STAAR Surgical (STAA) Q1 2026: China Drives 120% Sales Surge, Margin Leverage Emerges
STAAR Surgical’s Q1 marked a decisive reset as China sales fueled a triple-digit revenue jump and operating leverage returned, with inventory and channel noise now resolved. The company’s disciplined execution, new product traction, and cost control signal a durable path to profitability, but management remains cautious on forward guidance amid macro and geopolitical uncertainty. Investors should watch for margin sustainability and China demand signals as the year unfolds.
Summary
- China-Led Momentum: Premium lens adoption and normalized channel inventory restored growth visibility.
- Margin Inflection: Gross margin and EBITDA turned sharply positive as cost actions took hold.
- Guidance Caution: Management withheld annual forecasts, citing global volatility and demand unpredictability.
Business Overview
STAAR Surgical develops, manufactures, and sells implantable lenses for refractive vision correction, primarily the EVO and EVO Plus ICLs (Implantable Collamer Lenses, a type of phakic intraocular lens for myopia and astigmatism). The company’s revenue is driven by lens sales to ophthalmic surgeons and clinics, with China, the United States, and Japan as key markets. Major segments include China (largest by revenue), the Americas (notably the U.S.), and Rest of World (ROW), with lens-based refractive surgery as the core business model.
Performance Analysis
STAAR delivered a breakout Q1, with net sales up 119.6% year over year, led by China’s rebound and the commercial launch of EVO Plus. The U.S. posted over $6 million in sales—its highest ever—despite broader laser vision correction weakness, and ex-China markets grew modestly amid Middle East and India headwinds. Adjusted EBITDA swung positive, reflecting both top-line growth and the impact of 2025’s cost actions.
Gross margin expanded to 73.6%, up nearly 8 points YoY, as Swiss manufacturing scale, lower inventory provisions, and reduced freight costs offset lingering higher unit costs from prior production lulls. Operating expenses fell 18% excluding one-time items, with management reiterating a $225 million full-year spend target. Cash levels remain robust at $163.9 million with no debt, though Q1 outflows included annual bonuses and one-off costs.
- China Demand Reset: Channel inventory normalized, with Q1 sales closely matching in-market consumption.
- EVO Plus Premiumization: Early adoption outpaced expectations, supporting ASP (average selling price) resilience in China despite global price pressure.
- Operating Leverage Returns: Cost discipline and manufacturing efficiency drove a sharp swing to profitability.
Overall, Q1 marks the first “clean” quarter since 2024, with previous inventory and merger-related disruptions now resolved, giving investors a truer baseline for modeling forward performance.
Executive Commentary
"We have now largely moved past many of the challenges that we faced in 2025... Those issues are behind us. Now, turning to Q1, we see that we're off to a very positive start as reflected in our first quarter results."
Warren Faust, Interim Co-CEO, President, and Chief Operating Officer
"Adjusted EBITDA was $24.4 million compared to an adjusted EBITDA loss of $26.3 million in the prior year quarter, reflecting higher net sales, improved gross profit, and the benefits of the cost actions we've implemented since 2025."
Deborah Andrews, Interim Co-CEO and Chief Financial Officer
Strategic Positioning
1. China as Core Growth Engine
China accounted for over half of Q1 sales, with normalized inventory and stable refractive demand underpinning performance. Management emphasized continued share gains in premium lens-based surgery and strong EVO Plus uptake, positioning the region as the primary near-term driver.
2. U.S. Market Expansion and Indication Growth
U.S. sales exceeded $6 million, rising 22% YoY, even as the broader laser vision correction market contracted. FDA approval for patients aged 45-60 expands the addressable market by an estimated 8 million potential patients, supporting a multi-year growth runway as lens-based correction gains traction.
3. Manufacturing and Supply Chain Optimization
The Nidao, Switzerland facility now supplies all China-bound lenses, mitigating tariff exposure and enabling rapid scale-up for EVO Plus. Management highlighted the plant’s ability to flex production in response to premium product demand, with further cost benefits expected as volumes rise in H2.
4. Disciplined Capital Allocation and Cost Structure
Spending discipline remains a top priority, with OpEx down 18% YoY and a clear path to operating leverage. Cash preservation and measured commercial investment were reiterated, especially in volatile or lower-margin international markets.
5. Innovation and Product Pipeline
Early success of EVO Plus validates STAAR’s innovation strategy, with premium price points and clinical differentiation supporting both ASPs and surgeon adoption. Management is focused on expanding the pipeline and leveraging feedback from early adopters to refine future offerings.
Key Considerations
Q1’s results represent a strategic inflection, with channel normalization and premium product adoption restoring growth visibility and profitability. However, management’s refusal to provide full-year guidance signals ongoing caution amid a complex operating backdrop.
Key Considerations:
- China Channel Clarity: Inventory is now at or below six-month contractual targets, with in-market sales closely matching shipments—a key risk removed.
- Premium Mix Tailwind: EVO Plus adoption is driving a mix shift to higher ASPs in China, partially offsetting global price pressure.
- Margin Sustainability: Gross margin expansion is supported by lower cost of goods and Swiss plant scale, but H2 performance depends on volume ramp and input cost stability.
- Geopolitical and Macro Exposure: Middle East and India sales were impacted by external disruptions, highlighting ongoing vulnerability in smaller markets.
- Guidance Reluctance: Management’s unwillingness to provide annual forecasts reflects uncertainty around China seasonality and broader macro risks.
Risks
STAAR faces material uncertainty tied to China demand seasonality, macroeconomic volatility, and potential geopolitical shocks that could disrupt supply chains or dampen procedure volumes. Competitive risks are rising, with new entrants like iBright in China and global price pressure from alternative refractive procedures. Management’s guidance caution underscores the unpredictability of both top-line growth and margin trajectory, especially in the face of external shocks or slower-than-expected premium product adoption.
Forward Outlook
For Q2, STAAR Surgical management:
- Did not provide explicit revenue or earnings guidance, citing ongoing macro and geopolitical uncertainty.
- Reiterated a full-year 2026 OpEx target of $225 million, with spending expected to rise in quarters with major trade shows.
Gross margin is targeted to exit the year near 75%, with H2 improvement expected as Swiss facility volumes ramp. Management signaled optimism for a “good Q2,” referencing historic seasonality in China, but stopped short of quantifying expectations due to demand unpredictability and global risk factors.
Takeaways
STAAR Surgical’s Q1 marks a pivotal reset, with China demand, inventory normalization, and premium product adoption restoring growth and margin leverage.
- China’s stabilized channel and premium mix are now the primary growth and margin levers, but seasonality and macro risk remain key variables.
- Disciplined spending and Swiss manufacturing scale underpin margin expansion, though management is wary of near-term volatility.
- Investors should monitor China procedure trends, EVO Plus ramp, and management’s willingness to reinstate guidance as signals of sustained momentum.
Conclusion
STAAR Surgical has emerged from a turbulent period with renewed growth and profitability, led by China and premium lens adoption. While operational discipline and innovation are delivering results, management’s guidance restraint and external risk factors warrant continued vigilance. The next quarters will test the durability of this reset as macro and competitive dynamics evolve.
Industry Read-Through
STAAR’s Q1 highlights the global shift from laser vision correction to lens-based refractive procedures, with premium product innovation and channel normalization as key enablers. China’s stabilization and premiumization set a template for other device makers seeking growth in emerging markets, though price sensitivity and regulatory volatility remain universal challenges. Margin expansion via manufacturing scale and disciplined OpEx is a critical read-through for medtech peers navigating post-pandemic cost structures. Sector-wide, management caution on guidance signals a broader hesitance to call a durable rebound until macro headwinds abate.